분자유전학실험실 (단국대학교 분자생물학과)



 이성욱 ( 2015-09-24 07:12:48 , Hit : 939
 UPDATE 2-Gilead experimental drug fights all forms of hep C: data


Markets  |  Mon Sep 21, 2015 12:48pm EDT
Related:  Stocks,  Regulatory News,  Markets,  Healthcare  

By Natalie Grover

(Reuters) - Gilead Sciences Inc is edging closer to the approval of the first drug to fight all forms of hepatitis C as the drugmaker's experimental combination showed high rates of effectiveness in four late-stage studies.

The trials were evaluating a once-daily, fixed-dose combination of the drugmaker's approved hep C blockbuster, Sovaldi, with experimental NS5A inhibitor velpatasvir.

The combination is Gilead's second single-tablet treatment for the viral infection. Harvoni, its approved drug, targets the most common form - genotype 1 infections.

The main goal of each trial testing the experimental combination was to achieve a cure 12 weeks after the completion of therapy.

Of the 1,053 patients treated with the drug for 12 weeks in three trials, 98 percent were cured.

Data from the fourth trial, in more advanced and weaker patients, showed higher cure rates when patients also received ribavirin, an older antiviral.

Treatment-related side effects caused the death of nine patients in the trial, the company said.

The combination reduces the need for genotyping and potential confusion about which regimen works in which patients, UBS AG's Matthew Roden said.

Gilead's twin blockbuster hep C offerings, Sovaldi and Harvoni, brought in combined sales of about $4.9 billion last quarter.

Harvoni is expected to remain the treatment of choice in genotype 1, given it is taken for eight weeks, JP Morgan's Cory Casimov said.

Gilead's Sovaldi/velpatasvir combination demonstrated significant cure rates after 12 weeks.

William Blair's John Sonnier said the combination along with Gilead's GS-9857 could decrease treatment to six weeks while maintaining pan-genotypic potency.

In July, the FDA approved two new treatments for less common forms of hep C - AbbVie Inc's Technivie for genotype 4 and Bristol-Myers Squibb Co's Daklinza for genotype 3.

"A single, pan-genotypic approach may be particularly attractive in regions outside the United States where genotyping is less routine (or not possible)," Casimov said.

The Sovaldi/velpatasvir combination bodes well for Gilead to penetrate markets outside the United States, where non-genotype 1 hep C is more prevalent, Sonnier added.

The Foster City, California-based drugmaker plans to file marketing applications for the combination by the fourth quarter.

The company's stock, however, fell 2 percent after Hillary Clinton said she will propose a plan to take on specialty drug price gouging. S&P 500 Healthcare index was down 1 pct. (Reporting by Natalie Grover in Bengaluru; Editing by Anil D'Silva and Don Sebastian)







1207   Cancer Onset May Be Caused by Immune System Fighting Viruses  이성욱 2017/08/25 872
1206   Resistance to HIV Engineered Via CRISPR  이성욱 2017/08/07 880
1205   Zika Update  이성욱 2016/03/15 884
1204   [바이오토픽] 드디어 올 것이 왔다: CRISPR, 생존가능 인간배아의 질병초래 유전자 교정 성공  이성욱 2017/08/03 886
1203   “유전자 치료 법률 금지 한국 유일” vs “생명체 설계도 바꾸는 건 문제”  이성욱 2017/08/28 890
1202   CRISPR Corrects RNA-based Disease Defects  이성욱 2017/08/14 894
1201   [바이오토픽] 중국, 최초의 유전체편집 아기 탄생  이성욱 2018/11/27 903
1200   CRISPR Fixes Stem Cells Harboring Blindness-Causing Defect  이성욱 2016/02/01 907
1199   First In Vivo Human Genome Editing to Be Tested in New Clinical Trial  이성욱 2017/05/18 911
1198   [바이오토픽] FDA 자문위원회, CAR-T(chimeric antigen receptor T cell) 승인 만장일치로 권고  이성욱 2017/07/14 919
1197   ‘단세포 인공생명체’ 눈앞에 성큼  이성욱 2017/03/11 921
1196   유전자치료제 '인보사' 연골재생 입증못해도 허가받은 까닭  이성욱 2017/07/14 925
1195   CRISPR Can Tag RNA  이성욱 2016/03/26 930
1194   Engineered Human Liver Tissue Grows in Mice  이성욱 2017/07/25 930
1193   Revisiting CAR T-Cells for Treating HIV Shows Promise  이성욱 2016/07/19 932
1192   독감바이러스의 ‘RNA 도둑질’  이성욱 2017/05/08 933
1191   RNA May Surpass DNA in Precision Medicine  이성욱 2016/03/23 937
  UPDATE 2-Gilead experimental drug fights all forms of hep C: data  이성욱 2015/09/24 939
1189   노벨 생리의학상 유감(有感)  이성욱 2015/10/06 940
1188   Editas Expands CRISPR Capabilities through New Technology Licensing  이성욱 2016/12/22 940

[1][2][3] 4 [5][6][7][8][9][10]..[64] [다음 10개]
 

Copyright 1999-2024 Zeroboard / skin by ROBIN